Prostaglandins in pathogenesis and treatment of multiple sclerosis.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) characterized by inflammation, demyelination, axonal loss, and gliosis. The inflammatory lesions are manifested by a large infiltration and a heterogeneous population of cellular and soluble mediators of the immune system, such as T cells, B cells, macrophages, and microglia, as well as a broad range of cytokines, chemokines, antibodies, complement, and other toxic substances. Prostaglandins (PGs) are arachidonic acid-derived autacoids that have a role in the modulation of many physiological systems including the CNS, respiratory, cardiovascular, gastrointestinal, genitourinary, endocrine, and immune systems. PG production is associated with inflammation, a major feature in MS that is characterized by the loss of myelinating oligodendrocytes in the CNS. With respect to the role of PGs in the induction of inflammation, they can be effective mediators in the pathophysiology of MS. Thus use of agonists or antagonists of PG receptors may be considered as a new therapeutic protocol in MS. In this review, we try to clarify the role of PGs in immunopathology and treatment of MS.
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran 14155, Iran. mirshafiey@tums.ac.ir
Abbas
A
Mirshafiey
Farhad
F
Jadidi-Niaragh
D000818:Animals; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism*; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D011453:Prostaglandins / Q000819:agonists / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000819:agonists / Q000037:antagonists & inhibitors
D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011982:Receptors, Prostaglandin